
Ngenic Q1 2023 - Review

Redeye maintains a positive outlook on Ngenic following its Q1 2023 report, which showcased robust growth and impressive margins. The demand for Ngenic's products remain high and the company has issued a SEK10.2m convertible loan to expedite further growth. As a result, we anticipate stronger performance and have adjusted our short-term forecast accordingly. The stellar performance, coupled with the company's strategy to accelerate growth, gives rise to a new fair value range and base case.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Ngenic Q1 2023 - Review](#)